AFP ASX Week ended 31 Jul 2026

Weekly Investor Report

AFT Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 4.10 AUD
9.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 32.1% above the Trend Line and sits at 98.5% of its 52-week range. The latest completed week returned 9.3%, after a 36.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 48/100. Near-term considerations: price is close to its 52-week high.

Setup score 74 out of 100
Latest Close 4.10 AUD 31 Jul 2026
1W Return 9.3% latest completed week
4W Return 36.2% short-term follow-through
12W Return 29.1% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 3.4x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 36.15% based on similar historical setup states.
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 9.3% Latest completed week; four-week move 36.2%. Indicator stack 48/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 36.15% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 48/100 18 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 32.1% above the Trend Line and sits at 98.5% of its 52-week range. The latest completed week returned 9.3%, after a 36.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 3.4x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.47

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 36.2% over four weeks, 29.1% over 12 weeks, and 71.7% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W9.3%
4W36.2%
12W29.1%
26W33.0%
52W71.7%
Active trend streak4 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.06Latest activity-pressure read.
Pressure change2632.8%Four-week change in activity pressure.
Leadership37.63Latest relative-leadership reading.
RS change585.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength23/100Blend of value, momentum, and quality. Underlying universe rank 78; rank 1 is best.
Value7/100Relative valuation strength. Underlying universe rank 94; rank 1 is best.
Quality15/100Profitability and accounting quality. Underlying universe rank 86; rank 1 is best.
Momentum94/100Medium-term price momentum. Underlying universe rank 7; rank 1 is best.
Growth94/100Revenue and earnings growth. Underlying universe rank 7; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework31/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
26.7x
Price divided by trailing earnings.
Price / sales
1.6x
Market value relative to trailing revenue.
EV / EBITDA
15.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-4.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
42.6%
Gross profit retained from each unit of revenue.
Operating margin
6.9%
Operating profit retained from revenue.
Free-cash-flow margin
-7.7%
Free cash flow generated from revenue.
Return on invested capital
8.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
22.2%
Latest one-year revenue growth.
EPS growth
23.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-410.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.4%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 18 relevant articles.

1 positive · 15 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-0.7%Distance below the 52-week high.
13-week volatility7.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 268 weeks finished lower.
Best week+14.0%Week of 24 Jul.
Worst week-14.4%Week of 15 May.
Latest week+9.3%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains5
Flat weeks6
Modest losses5
Sharp losses3
Recent vol7.2%13-week weekly-return volatility.
Base vol5.7%52-week weekly-return volatility.
Up/down split24/18Count of positive and negative weeks in the 52-week window.
Average skew5.7% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape68/100

Trend, activity pressure, participation, and risk combine to a 68/100 tape read.

 Indicator analysis60/100

Latest 12-week confirmation: trend 5/12, activity pressure 10/12, relative leadership 12/12.

Activity pressure 0.50; 2 reversal markers Next-Week ExpectancyNegative 36.15%

Next-week expectancy is negative with a 36.15% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors32/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 51; Small Cap Core rank 87 SVQF31/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 182.0 of 262 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment48/100

Weighted news tone is neutral across 18 relevant articles.

AFT Pharmaceuticals Chair David Flacks to Step Down Within a Year as Revenue Surges to $254.7 Million Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.10 AUD9.3%3.10 AUD2.84 AUD1.0637.6334.5KOn
24 Jul 20263.75 AUD14.0%3.07 AUD2.84 AUD0.7130.1813.2KOn
17 Jul 20263.29 AUD5.1%3.04 AUD2.84 AUD0.3614.856.1KOn
10 Jul 20263.13 AUD4.0%3.03 AUD2.84 AUD0.229.7414.6KOn
3 Jul 20263.01 AUD0.0%3.03 AUD2.84 AUD0.045.492.0KOff
26 Jun 20263.01 AUD0.0%3.04 AUD2.84 AUD0.136.740Off
19 Jun 20263.01 AUD-1.5%3.04 AUD2.84 AUD0.296.398.5KOff
12 Jun 20263.06 AUD-5.5%3.04 AUD2.84 AUD0.278.772.4KOff
5 Jun 20263.24 AUD0.9%3.03 AUD2.85 AUD0.1117.985.1KOn
29 May 20263.21 AUD5.6%3.02 AUD2.85 AUD0.0015.9816.4KOff
22 May 20263.04 AUD11.7%3.00 AUD2.85 AUD-0.2011.2219.0KOff
15 May 20262.72 AUD-14.4%2.98 AUD2.85 AUD-0.300.2210.4KOff
8 May 20263.18 AUD0.0%2.98 AUD2.86 AUD-0.1015.680On
1 May 20263.18 AUD1.3%2.96 AUD2.86 AUD-0.3616.3660On
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.